MYOV stock: buy or sell?
May 21st, 2019
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases.
Should I buy MYOV stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Myovant Sciences stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Myovant Sciences stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 2 ratings published for MYOV stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
MYOV stock analysis
Shares of Myovant Sciences closed today at $12.78 and rose a shining 2.08%.
Shares of Myovant Sciences rose a shining 2.08% and closed at $12.78. Since April 11th when MYOV stock price broke down the SMA200d line, it slid $-9.10 per share (-41.59%). MYOV is soaring again after a 15.87% correction from its last top on Wednesday at $13.93. Since SMA50d and SMA100d crossed up on March, MYOV price slid a -40.92%.
After sliding a chilling -42.23% in a week last week, Myovant Sciences closed this week at $12.78 and soared a nice 2.40%.
Since price and 40-weeks moving average lines crossed down early April, MYOV fell $-11.66 per share (-47.71%). Stocks under the 200d moving average line are usually not recommended for average traders. Far behind is the all-time high Myovant Sciences hit late September 2018 and since then the price is -53.44% below that top.
MYOV stock price history
MYOV IPO was on October 27th, 2016 at $15.00 per share1. Since then, MYOV stock lost a -14.80%, with a yearly average of -7.40%.
1: Adjusted price after possible price splits or reverse-splits.
MYOV stock historical price chart
MYOV stock reached all-time highs on September with a price of $27.45.
MYOV stock price target is $25.00Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we found 2 price forecasts for Myovant Sciences stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Myovant Sciences reported its latest financial data, posting a slightly fine growth for the Earnings per Share (EPS) ratio. Analyst expected $-0.99 per share, but Myovant Sciences posted $-1.04.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn , Myovant Sciences annual turnover to M USD from marked in . , its profit margin (compared to sales) to , that is million.
Quarterly financial resultsReported quarter income marked $-70.63 million with a profit margin of . Profit margin stayed stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Myovant Sciences sales marked a tight move and remained steady a nan%. Looking back to recent quarterly results, Myovant Sciences posted 7 positive quarters in a row.
Myovant Sciences ownershipWhen you are planning to invest in a stock, it's always worth to overview its ownership structure.
Myovant Sciences shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 67.07% of all shares.
In case of Myovant Sciences stock, 31.04% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for MYOV stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Myovant Sciences:
|Market cap||$905.0 M||$366.8 M||$180.5 M|
|Total shares||70.8 M||120.7 M||49.2 M|
|Float shares||19.6 M||109.4 M||49.1 M|
|- Institutional holdings (%)||31.0%||95.2%||72.8%|
|- Insider holdings (%)||67.1%||2.5%||0.2%|
|Shares in short selling||0.0%||0.0%||0.0%|
|Tuesday, May 21st, 2019|
|Day range||$12.42 - $12.97|
|Average true range||$1.10|
|50d mov avg||$20.00|
|100d mov avg||$19.71|
|200d mov avg||$20.48|
Myovant Sciences performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared Myovant Sciences against PDL BioPharma and Pieris Pharmaceuticals in the following table: